ADC Industry These are the 11 approved ADC’s also targeted drug delivery technology, I am going to bypass Mylotarg as the drug was approved first in 2000 but due to adverse effects it got black box warning later in 2010 it was withdrawn and in 2017 it was approved again and still has the warning.
Note the market sizes quoted below are for the cancers mentioned and not for late stages of them but I think it would be good to include them as a references.
Adcetris targeting Hodgkin lymphoma. The Non-Hodgkin Lymphoma Therapeutics market in the U.S. is estimated at $1.6 Billion in the year 2020 and systemic anaplastic large-cell lymphoma (rare condition with low prevalence), the drug is commercialized by Seattle Genetics (among others) now known as Seagen, approved in 2011.
They sold in 2021 $344.5M, 2020 $658.6M, 2019 $627.7M, 2018 $476.9M, 2017 $307.6M etc. so the sales of the drug has a decent growth rate YOY. Adcetris Costs $4,500 Per Vial, or over $100,000 for a course of Lymphoma treatment.
https://www.biochempeg.com/article/74.html
Kadcyla approved in 2013 targeting HER2-positive metastatic breast cancer following treatment with trastuzumab and a maytansinoid. The therapeutic market in the US is estimated to be more than $4B the drug is commercialized by Roche, sales of the drug $631M in 2021 so far, 540$M IN 2020, $876M in 2019, 637$M in 2018 so sales are steady in the last few years. The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) and price is $3,451 per 100 mg.
Besponsa approved in 2017 targeting relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia, this condition seems to have low prevalence with about 876,000 people were globally affected in 2015, commercialized by Pfizer/Wyeth. Pfizer sold so far in the US only $42 M in 2021 and $36M in 2020 etc.
Lumoxiti approved in 2018 targeting adults with relapsed or refractory hairy cell leukemia. The hairy cell leukemia therapeutics market in the US is projected to be at$2.4B. AstraZeneca licensed the EU and US rights of Lumoxiti to Innate Pharma for $50 million upfront plus future milestone payments of up to $25 million, later on Innate Pharma returned US and EU Lumoxiti commercialization rights back to AstraZeneca.
The cost for Lumoxiti intravenous powder for injection 1 mg is around $2,217 for a supply of 1 powder for injection, the dosage is 0.04 mg/kg IV on days 1, 3, and 5 of each 28-day cycle; infuse over 30 minutes. Continue for maximum of 6 cycles or until disease progression or unacceptable toxicity occurs. Looking at half year results of AstraZeneca it seems like they gave the sale numbers of all their oncology drugs and not individual drugs so I don’t know the sales of the drug.
Polivy approved in 2019 targeting relapsed or refractory diffuse large B-cell lymphoma. The global relapsed or refractory diffuse large B-cell lymphoma market is estimated to be valued at $ 1.3 B in 2021. Roche sold internationally in 2021 $94M ($40M in US), $169M in 2020, $51M in 2019 so again a healthy sale growth for their drug. The drug costs in the region of $90,000 for a four-month course.
Padcev approved in 2019 targeting adult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy. The global metastatic urothelial carcinoma market was valued at $725.9M in 2019. Seattle Genetics now Seagen sold $152M in 2021, $222M in 2020.The annual cost of the drug estimated at $100,000.
Enhertu approved in 2019 targeting adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens.
A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%. Again AstraZeneca bundled up their oncology drugs’ sales so I cannot find sales numbers for this drug.
The cost for Enhertu intravenous powder for injection 100 mg is around $2,479 for a supply of 1 powder for injection and the dosage is 5.4 mg/kg IV q3Weeks (21-day cycle)
Continue until disease progression or unacceptable toxicity.
Trodelvy approved in 2020 targeting adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for patients with relapsed or refractory metastatic disease, the market value for TNBC in 2017 was about $440M. Immunomedics the founder of the drug in 2020, was acquired by Gilead Sciences. They sold $532M in 2021so far versus $49M in 2020 since the launch of the drug in 2020, impressive sale growth! The cost for Trodelvy intravenous powder for injection 180 mg is around $2,239 for a supply of 1 powder for injection as per dosage days 1 and 8: 10 mg/kg IV continue treatment until disease progression or unacceptable toxicity.
Blenrep approved in 2020 targeting adult patients with relapsed or refractory multiple myeloma, The global multiple myeloma therapeutics market was valued at USD 7.5 billion in 2015 and is projected to grow at a CAGR of 16.6% over the forecast period.
GlaxoSmithKline sold$42M in 2021, $33M IN 2020. The cost for Blenrep intravenous powder for injection 100 mg is around $8,780 for a supply of 1 powder for injection. The recommended dosage of BLENREP is 2.5 mg/kg of actual body weight given as an intravenous infusion over approximately 30 minutes once every 3 weeks until disease progression or unacceptable toxicity.
Zynlonta approved in 2021 targeting Large B-cell lymphoma. Large B-cell Lymphoma market size in 7MM was $ 2,6B in 2017. As per company:
“ZYNLONTA generated net sales of $3.8 million for the two-month period following accelerated U.S. Food and Drug Administration (FDA) approval on April 23, 2021, reflecting patient demand with no material inventory build.”
The cost for Zynlonta intravenous injection 10 mg is around $24,544 for a supply of 1 injection, the dosing is Cycles 1-2: 0.15 mg/kg IV q3Weeks, Cycle 3 and thereafter: 0.075 mg/kg IV q3Weeks.
Now these are all ADCs but their technology is very similar to PDCs and these drugs often targeting relapsed and late stage cancers like PDCs. Also many of these companies have multiple commercial and R&D products so their market caps rightfully is much bigger than THTX.To put it in perspective THTX as per their trial for now is targeting recurrent advanced TNBC(TNBC Market Size in the 7MM was found to be USD 438 Million in 2017. The US accounted for the largest market size of TNBC, in comparison to the other 7MM countries), epithelial ovarian cancer (The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.), endometrial cancer (Endometrial Cancer Treatment Market is estimated to value over USD 12.4 billion by 2027 end with a CAGR of over 5.9% during the forecast period 2020 to 2027. Endometrial cancer is one of the most prominently observed cancers in women.), colorectal cancer (The global Colorectal Cancer Therapeutics market size is projected to reach USD 17070 million by 2027, from USD 12130 million in 2020, at a CAGR of 4.9% during 2021-2027. The global Colorectal Cancer Therapeutics market is segmented by company, region (country), by Type, and by Application.) and pancreatic cancer (Pancreatic Cancer Market is estimated to value over USD 4.7 billion by 2027 end with a CAGR of over 10.2% during the forecast period 2020 to 2027. Technological advancements in the field of therapeutics, burgeoning incidences of cancer are some key factors that drive the growth of the market). Also all those indication have to have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. The point is some of these ADCs are selling well specifically the ones which have been in the market longer and targeting cancers with sizable prevalence. Now THTX if their technology works could have multiple shots on various cancers some with multi B market opportunities.